AstraZeneca Outlines Precision Medicine Strategy for DNA Damage Response Portfolio | GenomeWeb

CHICAGO (GenomeWeb) – Ovarian cancer patients with BRCA mutations lived nearly five months longer when they took AstraZeneca's Lynparaza (olaparib) as a means to stave off the disease and some of them have been on the drug for at least five years, researchers reported at the American Society of Clinical Oncology's annual meeting held here this week.

The data is part of AstraZeneca's strategy to expand the uses of Lynparza, as well as build an entire portfolio of products that target DNA damage response.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.

Dec
08
Sponsored by
Personal Genome Diagnostics

This online seminar will discuss the application of circulating tumor DNA (ctDNA) sequencing to evaluate the emergence of resistance mutations during therapy.